You are here

Open

Reset

NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.


If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).

  1. PA-19-022: Advancing Imaging, Device Production, and Clinical Capabilities in Digital Dentistry (R43/R44 Clinical Trial Not Allowed)

    Release Date: 10-10-2018Open Date: 12-05-2018 Due Dates: Multiple Close Date: 09-05-2021

    Purpose Digital dentistry uses advanced materials and powerful manufacturing technologies aided by 3D imaging and processing software algorithms to produce dental devices and perform complex dental procedures. This Funding Opportunity Announcement (FOA) encourages innovation, optimization and customization of core technologies in digital dentistry that improve efficiency of oral healthcare delive ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  2. PAR-21-057: Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)

    Release Date: 11-19-2020Open Date: 01-22-2021 Due Dates: Multiple Close Date: 09-08-2023

    Background A biomarker is a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. Biomarker modalities are diverse, and can include ‘omics, imaging, behavioral, digital and physiologic endpoints, as well as composite biomarkers or biomarker signatures. Becaus ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  3. RFA-TR-21-010: Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases (U44 Clinical Trial Required)

    Release Date: 01-13-2021Open Date: 03-13-2021 Due Dates: Multiple Close Date: 01-13-2022

    A. Overview While there are thousands of rare diseases, the number of underlying etiologies is much smaller. Moreover, many disease etiologies underly multiple traditional diseases. This is most readily seen for rare monogenic diseases, where the most common etiologies include premature termination codons, protein misfolding, and abnormal RNA splicing. Other examples of rare disease shared molecu ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  4. RFA-HD-22-018: Biomarker Research to Support Fertility Regulation Development by Small Business (R43 Clinical Trial Optional)

    Release Date: 04-15-2021Open Date: 06-29-2021Due Date: 07-29-2021Close Date: 07-30-2021

    Purpose The purpose of this Funding Opportunity Announcement (FOA) is to invite SBIR applications to support and facilitate the development of new and/or improved clinical biomarkers and companion biomarker diagnostics (e.g., point of care and/or direct-to-consumer tests, DTC) to support the clinical development of non-hormonal contraceptive product(s) for men and women. Background Nearly half ...

    SBIRPhase IDepartment of Health and Human ServicesNational Institutes of Health
  5. PAR-21-233: Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

    Release Date: 04-23-2021Open Date: 07-10-2021 Due Dates: Multiple Close Date: 04-06-2024

    A. Overview Recent advances in biology offer unprecedented opportunities to discover new treatments for nervous system disorders. Biotherapeutic development, however, has inherent complexities with regards to characterization, manufacturing, delivery, and administration. Many academic laboratories and small business enterprises don’t have the full scope of expertise and resources available; thi ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  6. PAR-20-111: Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

    Release Date: 03-02-2020Open Date: 07-11-2020 Due Dates: Multiple Close Date: 05-08-2023

    A. Overview Recent advances in neuroscience offer unprecedented opportunities to discover new treatments for nervous system disorders. However, before a new chemical entity can be tested in a clinical setting, it must undergo a process of chemical optimization to improve potency, selectivity, and drug-like properties, followed by pre-clinical safety testing to meet the standards set by the Food a ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  7. PA-19-034 : Commercializing Understudied Proteins from the Illuminating the Druggable Genome Project (IDG) (R43/R44 Clinical Trial Not Allowed)

    Release Date: 10-24-2018Open Date: 12-05-2018 Due Dates: Multiple Close Date: 09-05-2021

    Background The human genome has revealed a great deal about the human proteome, though significant portions remain understudied. Only a subset of expressed proteins demonstrates the requisite properties to serve as targets for the development of therapeutics. Many bona fide drug targets likely remain to be discovered in the "Druggable Genome" (DG), which can be defined as a subset of the ~20,000 ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  8. PAR-19-061 : Computational Genomics and Data Science Opportunities for Small Business (R43/R44 Clinical Trial Not Allowed)

    Release Date: 11-09-2018Open Date: 12-05-2018 Due Dates: Multiple Close Date: 09-05-2021

    Background Since its inception the field of genomics has been grounded in computational approaches. All facets of genomic research, such as processing raw sequencing signals, assembling genomes, calling variants, deriving insight from population sequencing studies, and designing and studying the implementation of genomics in clinical settings, are dependent upon computational, analytical, statist ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  9. 75N91020R00043 : Detection, Diagnosis, Treatment, Prevention and Research of Pediatric Cancers and/or Rare Cancers

    Release Date: 11-20-2020Open Date: 11-20-2020Due Date: 07-23-2021Close Date: 07-23-2021

    Background About 11,050 children in the United States under the age of 15 will be diagnosed with cancer in 2020 (https://www.cancer.org/cancer/cancer-in-children/key-statistics.html). Cancer is the second leading cause of death in children ages 1 to 14. Similarly, as a group, rare cancers are the leading cause of cancer deaths in the United States (https://rarecancer.org/). For the purpose of this ...

    SBIRPhase IDepartment of Health and Human ServicesNational Institutes of Health
  10. PA-20-047: Development of Highly Innovative Tools and Technology for Analysis of Single Cells (SBIR) (R43/R44 Clinical Trial Not Allowed)

    Release Date: 01-08-2020Open Date: 03-05-2020 Due Dates: Multiple Close Date: 01-06-2023

    Background Single cell analysis has recently become an active area of research to uncover fundamental biological principles behind cell diversity, which are often masked and not amenable to the population analysis of cells. The past several years have witnessed a rapid advancement in the development of single cell technologies and analysis methods. Multiple single cell "-omics" approaches are eme ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government